-
2025 COMB · Oncology Frontier Sofa Dialogue丨Professors Tao Wang & Kun Wang: Charting the Future of Chinese Original Research in Breast Cancer
01 Oncology Frontier: At this meeting, you presented multiple original Chinese studies in HER2-positive breast cancer, including Professor Kun Wang’s neoCARHP trial. Among them, which captured your particular attention? Could…
-
Professor Sun Ruijuan: Optimizing Key Aspects of Hematopoietic Stem Cell Transplantation for Infant Leukemia | 13th Ludaopei Hematology Conference
On August 22–23, 2025, the 13th Ludaopei Hematology Conference was grandly held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease…
-
Professor Cao Xingyu: Clinical Management and Transplant Strategies in Mycosis Fungoides and Sézary Syndrome | 13th Ludaopei Hematology Conference
On August 22–23, 2025, the 13th Ludaopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease Foundation,…
-
Professor Jin Li & Professor Joon Oh Park: Carrying the Torch Forward with Unity and Collaboration — FACO as a Platform for Advancing Comprehensive Academic Cooperation and the Joint Progress of Asian Clinical Oncology
Themed “Asian Clinical Oncology—Collaboration and Innovation,” this year’s FACO meeting aimed to further strengthen academic exchange and cross-border cooperation, while helping China’s rapidly evolving innovative oncology therapeutics “go global” to…
-
ISEH 2025 | Harvesting the Fruits of Collaboration: China–Japan Symposium on Stem Cells and Cell Therapy Opens a New Chapter
Launching a New Chapter: Forty Years of Sino–Japanese Exchange in Hematology The symposium began with opening remarks from Prof. Tao Cheng, Director of the Institute of Hematology, CAMS. He recalled…
-
ESMO Global Insight | Professor Andrea Necchi: Disitamab Vedotin Plus Immunotherapy Nearly Doubles Overall Survival in Advanced HER2-Expressing Urothelial Carcinoma
The combination of antibody–drug conjugates (ADCs) with immunotherapy has delivered major breakthroughs across several tumor types, including urothelial carcinoma. At the 2025 European Society for Medical Oncology (ESMO) Congress, results from a pivotal Phase III trial (LBA7) were presented showing that the HER2-targeted ADC disitamab vedotin, combined with the PD-1 inhibitor toripalimab, nearly doubled overall…
-
Highlights from the 13th International Conference of the Federation of Asian Clinical Oncology (FACO 2025)
At the recent FACO 2025 Conference held in Shanghai, Dr. Joon Oh Park, President of KSMO and President-elect of FACO, shared his perspectives on the evolving landscape of cancer treatment…
Connecting Medical Expertise through Media